Why IMU is a multi multi bagger, page-21296

It’s a pleasure to welcome Kim to the Imugene team as a Non-Executive Director,” said Imugene’s Executive Chairman Paul Hopper. "Kim's extensive knowledge of the US mid-cap biotechnology ecosystem, and the drivers of company success, will be instrumental in supporting our ongoing efforts to expand our investor footprint and further accelerate our clinical development programs in a financially disciplined manner. (end quote)

So linking the media release on her appointment in mid 2023 and the bio describing her background in strategic financing etc for start up biotechs, and PH quote above.... I reckon she was involved in the CR and probably doing work to get deals in the US. The last bit is obviously my guess! GLTA and DYOR.